51 Matching Annotations
  1. Mar 2022
  2. Dec 2021
    1. Munro, A. P. S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Gokani, K., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kwok, J., … Appleby, K. (2021). Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet, S0140673621027173. https://doi.org/10.1016/S0140-6736(21)02717-3 s

  3. Nov 2021
  4. Oct 2021
    1. Pozzetto, B., Legros, V., Djebali, S., Barateau, V., Guibert, N., Villard, M., Peyrot, L., Allatif, O., Fassier, J.-B., Massardier-Pilonchéry, A., Brengel-Pesce, K., Yaugel-Novoa, M., Denolly, S., Boson, B., Bourlet, T., Bal, A., Valette, M., Andrieu, T., Lina, B., … Trouillet-Assant, S. (2021). Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination. Nature, 1–9. https://doi.org/10.1038/s41586-021-04120-y

    1. Hulme, W. J., Williamson, E. J., Green, A., Bhaskaran, K., McDonald, H. I., Rentsch, C. T., Schultze, A., Tazare, J., Curtis, H. J., Walker, A. J., Tomlinson, L., Palmer, T., Horne, E., MacKenna, B., Morton, C. E., Mehrkar, A., Fisher, L., Bacon, S., Evans, D., … Goldacre, B. (2021). Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: A cohort study using OpenSAFELY [Preprint]. Epidemiology. https://doi.org/10.1101/2021.10.13.21264937

  5. Aug 2021
  6. Jul 2021
  7. Jun 2021
    1. Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Gethings, O., Vihta, K.-D., Jones, J., House, T., VanSteenHouse, H., Bell, I., Bell, J. I., Newton, J. N., Farrar, J., Diamond, I., Rourke, E., Studley, R., Crook, D., Peto, T. E. A., Walker, A. S., & Pouwels, K. B. (2021). Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nature Medicine, 1–9. https://doi.org/10.1038/s41591-021-01410-w

  8. May 2021
  9. Apr 2021
    1. ReconfigBehSci. ‘@sarahflecke “Reports Emerging of Rare Types of Multiple Thrombosis, Bleeding, and Thrombocytopenia .. Similar to Disseminated Intravasc. Coagulation ... in Otherwise Healthy Individuals Shortly after Receiving ..AstraZeneca ..Vaccine. These Outcomes Are Not Included in the Present Analysis.”’ Tweet. @SciBeh (blog), 2 April 2021. https://twitter.com/SciBeh/status/1377984798422077446.

  10. Mar 2021
  11. Feb 2021
  12. Jan 2021
  13. Dec 2020
  14. Aug 2020
  15. Jul 2020
  16. Feb 2020
  17. Jul 2019
    1. The position of machine products in the civilized scheme of consumption serves to point out the nature of the relation which subsists between the canon of conspicuous waste and the code of proprieties in consumption. Neither in matters of art and taste proper, nor as regards the current sense of the serviceability of goods, does this canon act as a principle of innovation or initiative. It does not go into the future as a creative principle which makes innovations and adds new items of consumption and new elements of cost. The principle in question is, in a certain sense, a negative rather than a positive law. It is a regulative rather than a creative principle. It very rarely initiates or originates any usage or custom directly. Its action is selective only. Conspicuous wastefulness does not directly afford ground for variation and growth, but conformity to its requirements is a condition to the survival of such innovations as may be made on other grounds. In whatever way usages and customs and methods of expenditure arise, they are all subject to the selective action of this norm of reputability; and the degree in which they conform to its requirements is a test of their fitness to survive in the competition with other similar usages and customs.
  18. Jan 2019